Advertisement

Radiation Dose-Volume Effects in the Esophagus

      Publications relating esophageal radiation toxicity to clinical variables and to quantitative dose and dose–volume measures derived from three-dimensional conformal radiotherapy for non–small-cell lung cancer are reviewed. A variety of clinical and dosimetric parameters have been associated with acute and late toxicity. Suggestions for future studies are presented.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Curran Jr., W.
        • Scott C.
        • Langer C.
        • et al.
        Phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: Initial report of RTOG 9410.
        Proc ASCO. 2000; 19: 484a
        • Furuse K.
        • Fukuoka M.
        • Kawahara M.
        • et al.
        Phase III study of concurrent vs. sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer.
        J Clin Oncol. 1999; 17: 2692-2699
        • Cox J.D.
        • Pajak T.F.
        • Asbell S.
        • et al.
        Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: Analysis of 1244 cases from 3 RTOG trials.
        Int J Radiat Oncol Biol Phys. 1993; 27: 493-498
        • Timmerman R.
        • McGarry R.
        • Yiannoutsos C.
        • et al.
        Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancers.
        J Clin Oncol. 2006; 24: 4833-4839
        • Onishi H.
        • Shirato H.
        • Nagata Y.
        • et al.
        Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study.
        J Thoracic Oncol. 2007; 2: S94-S100
        • Choi G.B.
        • Shin J.H.
        • Song H.Y.
        • et al.
        Fluoroscopically guided balloon dilation for patients with esophageal stricture after radiation treatment.
        J Vascular Intervent Radiol. 2005; 16: 1705-1710
        • Singh A.K.
        • Lockett M.A.
        • Bradley J.D.
        Predictors of radiation-induced esophageal toxicity in patients with non-small cell lung cancer treated with three-dimensional conformal radiotherapy.
        Int J Radiat Oncol Biol Phys. 2003; 55: 337-341
        • Qiao W.-B.
        • Zhao Y.-H.
        • Zhao Y.-B.
        • et al.
        Clinical and dosimetric factors of radiation-induced esophageal injury: Radiation-induced esophageal toxicity.
        World J Gastroenterol. 2005; 11: 2626-2629
      1. CTC/CTCAE Codes. Available from: www.ctep.info.nih.gov/reporting/ctc.html. Last accessed December 15, 2009.

        • Werner-Wasik M.
        • Scott C.
        • Curran Jr., W.J.
        • et al.
        Correlation between acute esophagitis and late pneumonitis in patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) receiving concurrent thoracic radiotherapy (RT) and chemotherapy: A multivariate analysis of the Radiation Therapy Oncology Group (RTOG) database [Abstract].
        Proc ASCO. 2002; 21: 299a
        • Ahn S.-J.
        • Kahn D.
        • Zhou S.
        • et al.
        Dosimetric and clinical predictors for radiation- induced esophageal injury.
        Int J Radiat Oncol Biol Phys. 2005; 61: 335-347
        • Goldstein H.M.
        • Rogers L.F.
        • Fletcher G.H.
        • et al.
        Radiological manifestations of radiation-induced injury to the normal upper gastrointestinal tract.
        Radiology. 1975; 117: 135-140
        • Chapet O.
        • Kong F.-M.
        • Lee J.S.
        • et al.
        Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer.
        Radiother Oncol. 2005; 77: 176-181
        • Dieleman E.M.T.
        • Senan S.
        • Vincent A.
        • et al.
        Four-dimensional computed tomographic analysis of esophageal mobility during normal respiration.
        Int J Radiat Oncol Biol Phys. 2007; 67: 775-780
        • Kahn D.
        • Zhou S.
        • Ahn S.-J.
        • et al.
        Anatomically correct dosimetric parameters may be better predictors for esophageal toxicity than are traditional CT-based metrics.
        Int J Radiat Oncol Biol Phys. 2005; 62: 645-651
        • Bradley J.
        • Deasy J.O.
        • Bentzen S.
        • et al.
        Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma.
        Int J Radiat Oncol Biol Phys. 2004; 58: 1108-1113
        • Werner-Wasik M.
        • Pequignot E.
        • Leeper D.
        • et al.
        Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: A multivariate analysis of patients with lung cancer treated with non-operative therapy.
        Int J Radiat Oncol Biol Phys. 2000; 48: 689-696
        • Maguire Sibley GS.
        • Zhou S.M.
        • et al.
        Clinical and dosimetric predictors of radiation-induced esophageal toxicity.
        Int J Radiat Oncol Biol Phys. 1999; 45: 97-103
        • Belderbos J.
        • Heemsbergen W.
        • Hoogeman M.
        • et al.
        Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy.
        Radiother Oncol. 2005; 75: 157-164
        • Kim T.H.
        • Cho K.H.
        • Pyo H.R.
        • et al.
        Dose–volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.
        Int J Radiat Oncol Biol Phys. 2005; 62: 995-1002
        • El Naqa I.
        • Bradley J.
        • Blanco A.I.
        • et al.
        Multivariable modeling of radiotherapy outcomes including dose–volume and clinical factors.
        Int J Radiat Oncol Biol Phys. 2006; 64: 1275-1286
        • Wei X.
        • Liu H.H.
        • Tucker S.L.
        • et al.
        Risk factors for acute esophagitis in non–small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy.
        Int J Radiat Oncol Biol Phys. 2006; 66: 100-107
        • Rodriguez N.
        • Algara M.
        • Foro P.
        • et al.
        Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy.
        Int J Radiat Oncol Biol Phys. 2009; 73: 810-817
        • Takeda K.
        • Nemoto K.
        • Saito H.
        • et al.
        Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy.
        Int J Radiat Oncol Biol Phys. 2005; 62: 626-629
        • Saunders M.I.
        • Dische S.
        • Barrett A.
        • et al.
        Randomized multicentre trials of CHART vs. conventional radiotherapy in head and neck and non-small cell lung cancer: An interim report.
        Br J Cancer. 1996; 73: 1455-1462
        • Langer C.
        • Hsu C.
        • Curran W.
        • et al.
        Do elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy? A secondary analysis of RTOG 94-10.
        Int J Radiat Oncol Biol Phys. 2001; 51: 20-21
        • Antonadou D.
        • Coliarakis N.
        • Synodinou M.
        • et al.
        Randomized Phase III trial of radiation treatment plus/minus amifostine in patients with advanced-stage lung cancer.
        Int J Radiat Oncol Biol Phys. 2001; 51: 915-922
        • Leong S.S.
        • Tan E.H.
        • Fong K.W.
        • et al.
        Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small cell lung cancer.
        J Clin Oncol. 2003; 21: 1767-1774
        • Komaki R.
        • Lee J.S.
        • Milas L.
        • et al.
        Effect of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small cell lung cancer: Report of a randomized comparative trial.
        Int J Radiat Oncol Biol Phys. 2004; 58: 1369-1377
        • Movsas B.
        • Scott C.
        • Langer C.
        • et al.
        Phase III study of amifostine in patients with locally advanced non-small cell lung cancer receiving intensive chemoradiation: Radiation Therapy Oncology Group 98-01.
        J Clin Oncol. 2005; 23: 2145-2154
        • Burman C.
        • Kutcher G.J.
        • Emami B.
        • et al.
        Fitting of normal tissue tolerance data to an analytic function.
        Int J Radiat Oncol Biol Phys. 1991; 21: 123-135
        • Källman P.
        • Agren A.
        • Brahme A.
        Tumor and normal tissue responses to fractionated non-uniform dose delivery.
        Int J Radiat Biol. 1992; 62: 249-262
        • Emami B.
        • Lyman J.
        • Brown A.
        • et al.
        Tolerance of normal tissue to therapeutic irradiation.
        Int J Radiat Oncol Biol Phys. 1991; 21: 109-122
        • Ragazzi G.
        • Cattaneo G.M.
        • Fiorino C.
        • et al.
        Use of dose–volume histograms and biophysical models to compare 2D and 3D irradiation techniques for non-small cell lung cancer.
        Br J Radiol. 1999; 72: 279-288
        • Onimaru R.
        • Shirato H.
        • Shimizu S.
        • et al.
        Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers.
        Int J Radiat Oncol Biol Phys. 2003; 56: 126-135
        • Xiao Y.
        • Werner-Wasik M.
        • Michalski D.
        • et al.
        Comparison of three IMRT-based treatment techniques allowing partial esophagus sparing in patients receiving thoracic radiation therapy for lung cancer.
        Med Dosim. 2004; 29: 210-216
        • Stichcombe T.
        • Lee C.
        • Moore D.T.
        • et al.
        Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer.
        J Thoracic Oncol. 2008; 3: 1279-1285
        • Schild S.E.
        • McGinnis W.L.
        • Graham D.
        • et al.
        Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non–small-cell lung cancer.
        Int J Radiat Oncol Biol Phys. 2006; 65: 1106-1111
        • Blackstock A.W.
        • Ho C.
        • Butler J.
        • et al.
        Phase IA/IB chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer.
        J Thorac Oncol. 2006; 1: 434-440
        • Colevas A.D.
        • Setser A.
        The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials.
        J Clin Oncol. 2004; 22: 6098

      Comments

      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.